MSTN and rheumatoid arthritis: It should be noted that the study by Gonzalez-Ponce et al. identified a myostatin cut-off point of ≥17 ng/mL as a risk factor that doubled the risk of developing rheumatoid cachexia and tripled the risk of myopenia for patients with RA [63].